Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 245 participants.
Also called NCT01159249
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 245 participants
- Sponsor
- Registry
-
NCT01159249
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01159249. Non-randomized; no masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2012-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Vildagliptin
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01159249- Content hash
c6c6303e46cae61088b41cf10c01c5b4daba4aaa3fe92823e59bd2812817e99b